Cost-Effectiveness of Saxagliptin Versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
Nov 1, 2016, 00:00
10.1016/j.jval.2016.08.216
https://www.valueinhealthjournal.com/article/S1098-3015(16)30796-3/fulltext
Title :
Cost-Effectiveness of Saxagliptin Versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)30796-3&doi=10.1016/j.jval.2016.08.216
First page :
A898
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2786